Impact of Beta Blockers on Left Ventricular Reverse Remodeling Following Primary Coronary Intervention for ST-elevation Myocardial Infarction.

Background. Benefits of beta-adrenergic receptor blockers (BB) following ST-elevation myocardial infarction (STEMI) are based on data before primary percutaneous coronary intervention (PCI) became the therapeutic first choice. This study examined the relationship between BB dose and magnitude of left ventricular ejection fraction (LVEF) improvement in STEMI following primary PCI. Methods and Findings. A total of 235 STEMI patients following primary PCI who underwent echocardiography during the acute phase and over 6 months from onset were studied retrospectively. Serial LVEFs were assessed for three groups: no BB (n=33), carvedilol (n=163), and bisoprolol (n=42). Left ventricular reverse remodeling (RR) was defined as LVEF improvement ≥10%. All patients received fixed doses of BB and renin-angiotensin system inhibitor during observation. The median interval between echocardiographs was 526 days. The mean LVEF change was +2.6% (acute: 53.9±9.9%, chronic: 56.4±10.6%). Carvedilol and bisoprolol groups showed LVEF improvement, but none was seen in the no BB group (+3.7±6.5%, +3.8±6.9%, -4.2±5.0%, P<0.0001, respectively). The LVEF improvement effect was BB dose dependent. Therapy with BBs had a high rate of RR (no BB 0%, carvedilol 19.4%, bisoprolol 16.7%, P=0.0225, respectively). Multivariate analysis showed the following predictors of RR: baseline LVEF <50% and regular dose of BB, ≥10 mg of carvedilol or ≥1.25 mg of bisoprolol (Odds ratio 2.35, 95% Confidence Interval [CI] 1.12-5.02, P=0.0242; Odds ratio 4.45, 95% CI 2.06-10.27, P=0.0001). Conclusions. Immediate BB administration following primary PCI for STEMI provided a dose-dependent LVEF improvement. A LVEF <50% and regular dose of BB are predictors of RR.

[1]  C. Gale,et al.  Comparison of Early Versus Delayed Oral β Blockers in Acute Coronary Syndromes and Effect on Outcomes. , 2016, The American journal of cardiology.

[2]  M. Lai,et al.  Class effect of beta-blockers in survivors of ST-elevation myocardial infarction: A nationwide cohort study using an insurance claims database , 2015, Scientific Reports.

[3]  H. Krumholz,et al.  National assessment of early β-blocker therapy in patients with acute myocardial infarction in China, 2001-2011: The China Patient-centered Evaluative Assessment of Cardiac Events (PEACE)-Retrospective AMI Study. , 2015, American heart journal.

[4]  Mao Chen,et al.  Meta-Analysis of Relation Between Oral β-Blocker Therapy and Outcomes in Patients With Acute Myocardial Infarction Who Underwent Percutaneous Coronary Intervention. , 2015, The American journal of cardiology.

[5]  A. Furber,et al.  Relationship between beta-blocker and angiotensin-converting enzyme inhibitor dose and clinical outcome following acute myocardial infarction. , 2015, Circulation journal : official journal of the Japanese Circulation Society.

[6]  M. Hori,et al.  Minimal dose for effective clinical outcome and predictive factors for responsiveness to carvedilol: Japanese chronic heart failure (J-CHF) study. , 2013, International journal of cardiology.

[7]  J. DiNicolantonio,et al.  Meta-analysis of carvedilol versus beta 1 selective beta-blockers (atenolol, bisoprolol, metoprolol, and nebivolol). , 2013, The American journal of cardiology.

[8]  I. Komuro,et al.  Impact of beta blockade therapy on long-term mortality after ST-segment elevation acute myocardial infarction in the percutaneous coronary intervention era. , 2013, The American journal of cardiology.

[9]  Jane A. Linderbaum,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[10]  Jane A. Linderbaum,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[11]  E. V. Simon.  Beta-Blocker Use and Clinical Outcomes in Stable Outpatients With and Without Coronary Artery Disease , 2013 .

[12]  Deepak L. Bhatt,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Circulation.

[13]  Deepak L. Bhatt,et al.  β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. , 2012, JAMA.

[14]  D. Atar,et al.  ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation , 2013 .

[15]  Marco Merlo,et al.  Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment. , 2011, Journal of the American College of Cardiology.

[16]  Y. Hayashi,et al.  Lack of effect of oral beta-blocker therapy at discharge on long-term clinical outcomes of ST-segment elevation acute myocardial infarction after primary percutaneous coronary intervention. , 2010, The American journal of cardiology.

[17]  A. Dyer,et al.  beta-Blocker use following myocardial infarction: low prevalence of evidence-based dosing. , 2010, American heart journal.

[18]  M. Pfeffer,et al.  Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial). , 2009, The American journal of cardiology.

[19]  G. Fonarow.  Role of carvedilol controlled-release in cardiovascular disease , 2009, Expert review of cardiovascular therapy.

[20]  S. Yusuf,et al.  Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial , 2008, The Lancet.

[21]  C. O’loughlin,et al.  Improvement but no cure of left ventricular systolic dysfunction in treated heart failure patients , 2007, European journal of heart failure.

[22]  T. Kolias,et al.  Metoprolol Reverses Left Ventricular Remodeling in Patients With Asymptomatic Systolic Dysfunction: The REversal of VEntricular Remodeling with Toprol-XL (REVERT) Trial , 2007, Circulation.

[23]  S. Kopecky.  Effect of beta blockers, particularly carvedilol, on reducing the risk of events after acute myocardial infarction. , 2006, The American journal of cardiology.

[24]  Richard B Devereux,et al.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardio , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[25]  S. Kjeldsen,et al.  A Comparison of the Two β-Blockers Carvedilol and Atenolol on Left Ventricular Ejection Fraction and Clinical Endpoints after Myocardial Infarction , 2005, Cardiology.

[26]  S. Kjeldsen,et al.  A comparison of the two beta-blockers carvedilol and atenolol on left ventricular ejection fraction and clinical endpoints after myocardial infarction. a single-centre, randomized study of 232 patients. , 2005, Cardiology.

[27]  G. Lamas,et al.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.

[28]  S. Kernis,et al.  Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? , 2004, Journal of the American College of Cardiology.

[29]  S. Hosoda,et al.  Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. , 2004, American heart journal.

[30]  Shokei Kim,et al.  Effect of Diltiazem on Cardiac Remodeling in Rats Assessed by Doppler Echocardiography and mRNA Expression , 1999, Cardiovascular Drugs and Therapy.

[31]  W. Remme.  The Carvedilol and ACE-Inhibitor Remodelling Mild Heart Failure Evaluation Trial (CARMEN)—Rationale and Design , 2004, Cardiovascular Drugs and Therapy.

[32]  H. Dargie,et al.  Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial , 2001, The Lancet.

[33]  S. Takai,et al.  Local angiotensin II-generating system in vascular tissues: the roles of chymase. , 2001, Hypertension research : official journal of the Japanese Society of Hypertension.

[34]  K. Kugiyama,et al.  Aldosterone Production Is Activated in Failing Ventricle in Humans , 2001, Circulation.

[35]  P. Hildebrandt,et al.  Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. , 2000, Journal of the American College of Cardiology.

[36]  T. Yue,et al.  Comparison of bisoprolol and carvedilol cardioprotection in a rabbit ischemia and reperfusion model. , 2000, European journal of pharmacology.

[37]  A. Hjalmarson.  Cardioprotection with beta-adrenoceptor blockers. Does lipophilicity matter? , 2000, Basic Research in Cardiology.

[38]  A. Carayon,et al.  , Brigitte Angiotensin II Receptor Blockade and Role in Cardiac Fibrosis Activation of Cardiac Aldosterone Production in Rat Myocardial Infarction : Effect of , 1999 .

[39]  R. Senior,et al.  Carvedilol prevents remodeling in patients with left ventricular dysfunction after acute myocardial infarction. , 1999, American heart journal.

[40]  N Freemantle,et al.  beta Blockade after myocardial infarction: systematic review and meta regression analysis. , 1999, BMJ.

[41]  S. Gottlieb,et al.  Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. , 1998, The New England journal of medicine.

[42]  R. Senior,et al.  Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomized trial. , 1997, Circulation.

[43]  K. Adams,et al.  Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. , 1996, Circulation.

[44]  D. Renlund,et al.  Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. , 1995, Journal of the American College of Cardiology.

[45]  G. Lamas,et al.  Activation of neurohumoral systems in postinfarction left ventricular dysfunction. , 1993, Journal of the American College of Cardiology.

[46]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[47]  K. Swedberg,et al.  Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) , 1992, The New England journal of medicine.

[48]  R. Peto,et al.  Beta blockade during and after myocardial infarction: an overview of the randomized trials. , 1985, Progress in cardiovascular diseases.

[49]  A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results. , 1983, JAMA.

[50]  B. Brundage,et al.  Left Ventricular Volume from Paired Biplane Two‐dimensional Echocardiography , 1979, Circulation.